Fortress Biotech, Inc.
NASDAQ:FBIOBiotechnology
Healthcare
$1.77 -1.79%
-$0.06 today
- Market cap
- $59.03M
- Beta
- 1.23
- P/E (TTM)
- 0.7
- EPS (TTM)
- $4.05
52W Low $1.70High $4.53
Volume 0.19M
Average 0.43M
Income Statement
Follow revenue through to earnings.
Revenue
$63.26M
FY 2025 · Annual
+9.7% YoYOperating Income
-$70.22M
FY 2025 · Annual
Net Income
$6.82M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 68.79M | 75.74M | 84.51M | 57.68M | 63.26M |
| Cost of Revenue | 32.08M | 30.78M | 22.89M | 20.88M | 20.92M |
| Gross Profit | 36.71M | 44.97M | 61.62M | 36.8M | 42.34M |
| Gross Margin | 53.4% | 59.4% | 72.9% | 63.8% | 66.9% |
| Research & Development | 128.87M | 134.88M | 106.07M | 56.88M | 11.9M |
| Selling, General & Admin | 86.84M | 113.66M | 90.98M | 87.73M | 96.4M |
| Operating Expenses | 225.25M | 248.53M | 203.96M | 147.18M | 112.56M |
| Depreciation & Amortization | 6.79M | 9.35M | 6M | 4.46M | 4.66M |
| EBITDA | (146.17M) | (193.69M) | (135.72M) | (104.49M) | (20.17M) |
| EBITDA Margin | -212.5% | -255.7% | -160.6% | -181.2% | -31.9% |
| Operating Income | (188.54M) | (203.56M) | (142.34M) | (110.38M) | (70.22M) |
| Operating Margin | -274.1% | -268.8% | -168.4% | -191.4% | -111.0% |
| Interest Income | 649K | 1.4M | 3M | 2.68M | 2.49M |
| Interest Expense | 15.31M | 13.64M | 12.52M | 9.93M | 8.71M |
| Other Income / Expenses | 24.19M | (9.9M) | (11.29M) | (10.16M) | 36.69M |
| Income Before Tax | (164.35M) | (213.46M) | (153.63M) | (120.54M) | (33.54M) |
| Pre-Tax Margin | -238.9% | -281.8% | -181.8% | -209.0% | -53.0% |
| Income Tax Expense | 473K | 449K | 521K | 312K | (620K) |
| Net Income | (64.7M) | (86.58M) | (60.64M) | (46M) | 6.82M |
| Net Margin | -94.1% | -114.3% | -71.7% | -79.8% | 10.8% |
| EPS (Basic) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| EPS (Diluted) | (11.85) | (14.55) | (8.47) | (2.69) | (0.07) |
| 5.45M | 5.93M | 8.11M | 20.78M | 27.9M | |
| 5.45M | 5.93M | 8.11M | 20.78M | 279.02M |
FBIO Earnings Waterfall · TTM
NASDAQ:FBIO · Revenue to Net Income
Key Ratios
EPS$3.18
Gross Margin64.4%
Net Margin197.8%
P/E Ratio-0.3
P/S Ratio5.2
Analysis
$66.2M of revenue converted into $127.8M of net income for the selected period. Gross margin is 64.4% and net margin is 197.8%, showing how much revenue survives after costs and taxes. EPS is $3.18, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 29, 2026 | |
| 8-K | Current report | Oct 1, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 1, 2026 |
How much revenue does FBIO generate?
Fortress Biotech, Inc. (FBIO) reported $63.26M of revenue in fiscal 2025.
Is FBIO profitable?
Fortress Biotech, Inc. (FBIO) reported $6.82M of net income, with a net margin of 10.8%.
Continue the stock analysis
Jump to another research area for this company.